On January 7, 2022 Absci Corporation reported that inked a research pact with Merck (Press release, Biosortia Pharmaceuticals, JAN 7, 2022, View Source [SID1234607739]). Under the deal, Absci will leverage its Bionic Protein non-standard amino acid technology and its artificial intelligence-powered integrated Drug Creation Platform to create enzymes to meet Merck’s biomanufacturing applications .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Absci is eligible for up to $610 million in upfront fees and milestone payments for three targets. In addition, they are up for research funding and tiered royalties on any sales that come out of the partnership.